Please login to the form below

How to design patient services with social media within the ABPI code guidelines

In this blog, Senior Consultant Craig Moore, from the Blue Latitude Strategy team, discusses the application of the ABPI Code, including incorporating social media into digital patient services.



In the UK, the marketing of prescription medicine to health professionals and patients is carried out under strict regulatory oversight to protect and support high quality patient care. The ABPI Code of Practice for the Pharmaceutical Industry is administered by the Prescription Medicines Code of Practice Authority, and is a self-regulatory code that applies to the marketing of prescription medicines both to health professionals and the public as a whole.


When designing digital services and informational materials for prescription drugs or services, there are unique considerations that must be taken around how that information is accessed and used. In this blog, Senior Consultant Craig Moore, from the Blue Latitude Strategy team, discusses the application of the ABPI Code, including incorporating social media into digital patient services.


Do some 
market research to understand the customer needs: would patients be interested in the social media functionality; would they use it? Rounds of user research and user testing would highlight if this was important or not.
At Blue Latitude, the aim is to solve problems for clients following a number of solution design methodologies.

Host a 
PMCPA (Prescription Medicines Code of Practice Authority) training session and take the opportunity to get feedback on early solution concepts. Understand where other companies have breached the code and where you may run the risk with your own solutions. The PMCPA’s view is absolute; any company working with or providing services for the Pharma Industry needs to know the code. (Blue Latitude’s staff have all completed the introductory PMCPA training session).


Get cross-functional teams around a meeting table 
to highlight social media in the organisation. The corporate communication team handles social throughout most organisations. Silos mean that the information is not always shared. The development of the website/app should not be the main focus; the main focus should be to capture any company-wide issues or concerns about using social, and highlight areas of the code that are designed to support this. Take any objections away and incorporate them into the business case for the solution.


Consider the level of patient access
 in the kind of website/app you want to develop. Patient access will raise some red flags, especially from the pharma-covigilance teams. The fear would be that an increased perception of patients discussing product-related issues would lead to an inundation of Adverse Events or Product Complaints (AE/PC).

Initiate some monitoring pilots related to the therapy area
 in general. This will help establish a reporting process; defining clear roles and responsibilities as well as outlining clear project plans, objectives, and exit strategies. Always follow the guidelines, and go beyond them.


For example, use what you report (or consider to be) an AE/PC as a metric to demonstrate that social listening will not create an undue burden on internal resources. Once the process is established, expand monitoring into competitor products – there is no need to report AE/PC for competitors – then, move on to company-owned products.

Look at the possibility of developing a solution for closed patient communities
. The code explains how use of social media to discuss prescription medicines (for example, on Twitter) is seen as promotional. With closed patient communities, the challenge to the code/internal MLR compliance teams is to make sure to only allow access to prescribed patients. Canada, for example, uses product identification numbers and DIN to allow access to a patient programme or forum.


If you’d like to discuss digital solutions for patient communities or how the ABPI Code impacts digital services in more depth, we’d love to hear from youGet in touch!

To read more about regulations which impact marketing for Pharma, read our blog from guest poster Aurelie Pols on data security and privacy.

21st May 2015

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need
Blue Latitude Health
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need.
Blue Latitude Health
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence.
Blue Latitude Health
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry.
Blue Latitude Health
Six factors that drive a multiple sclerosis patient's choice of disease-modifying therapy
MS advocate Trishna Bharadia explains the numerous factors that lead patients to choose a disease-modifying therapy, including the important considerations healthcare professionals and pharma often forget.
Blue Latitude Health
Innovative approaches in the treatment of multiple sclerosis
Blue Latitude Health Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon.
Blue Latitude Health